ARDELYX, INC.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $407.3M $333.6M $124.3M $51.5M $7.8M $7.8M $5.1M $1.5M
Product sales net $82.6M $15.6M $0 $0 $0 $0
Licensing and collaboration revenue $39.5M $33.7M $5.8M $6.5M $4.5M $1.5M
Non-cash royalty revenue $2.2M $2.2M $2.0M $1.3M $583.0K $0
Cost of Revenue $39.5M $50.6M $17.8M $4.1M $1.0M $145.0K $600.0K $466.0K
Gross Profit $367.8M $283.1M $106.5M $47.3M $6.8M $7.6M $4.7M $2.1M
Gross Margin 90.3% 84.8% 85.7% 92.0% 87.2% 98.1% 91.7% 145.2%
Operating Expenses
Research & Development $71.5M $52.3M $35.5M $35.2M $91.1M $65.1M $71.7M $69.4M
SG&A Expense $337.2M $258.7M $134.4M $76.6M $72.3M $33.2M $24.3M $23.7M
Operating Income $-41.0M $-28.0M $-63.3M $-63.8M $-154.3M $-90.8M $-91.3M $-90.9M
Operating Margin -10.1% -8.4% -50.9% -123.9% -1,973.7% -1,171.4% -1,788.8% -6,165.9%
Interest Expense $5.0M $3.4M $4.5M $5.1M $5.7M $3.5M
Pretax Income $-60.6M $-38.9M $-65.5M $-67.2M $-158.2M $-94.3M $-94.6M $-91.3M
Income Tax Expense $969.0K $266.0K $547.0K $8.0K $4.0K $2.0K $303.0K $4.0K
Net Income $-61.6M $-39.1M $-66.1M $-67.2M $-158.2M $-94.3M $-94.9M $-91.3M
Net Margin -15.1% -11.7% -53.1% -130.6% -2,022.6% -1,216.9% -1,860.8% -6,189.7%
EPS (Basic) $-0.26 $-0.17 $-0.30 $-0.42 $-1.52 $-1.05 $-1.47 $-1.62
EPS (Diluted) $-0.26 $-0.17 $-0.30 $-0.42 $-1.52 $-1.05 $-1.47 $-1.62
Shares Outstanding (Basic) 241.0M 235.2M 219.3M 158.7M 104.2M 89.6M 64.5M 62.5M
Shares Outstanding (Diluted) 241.0M 235.2M 219.3M 158.7M 104.2M 89.6M 64.5M 62.5M
Dividends Per Share
← Newer Page 1 of 2 Older →